You just read:

Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes

News provided by

Eli Lilly and Company

Oct 02, 2018, 06:00 ET